Ipsen’s long-standing expertise spans the value chain, from active principle to finished product to the patient, with special expertise in gastrointestinal (GI) disorders, neurodegenerative pathologies and rheumatology, as well as a constantly expanding portfolio. We are also establishing a growing sustainable and autonomous Consumer Healthcare business.
- We have 16 brands in the Consumer Health portfolio covering six disease areas
- In 2017, total Consumer Health sales were €316.8 million, equivalent to 16.6% of our overall business
- We have 1600 employees in the Consumer Health division
- We operate in over 70 countries
- The Smecta brand grew by 4.1% in 2017
Within the Consumer Healthcare Division, we have collectively enhanced the sense of urgency in turning our business back to growth.
Benoit Hennion, Executive Vice President, Consumer Healthcare
OUR CONSUMER HEALTH STRATEGY
Ipsen has transformed our former physician-centric primary care model into a flourishing Consumer Health business, driving revenues through a mix of physicians’ prescriptions, recommendations by pharmacists and patients’ direct demand. Recently renamed “Ipsen Consumer Healthcare”, the division puts the patient first by designing simple, safe, effective and accessible treatments – an essential approach at a time when consumers are playing an increasingly active role in making their own treatment choices and are looking for convenient, ready-to-use solutions.
The last few years have been dedicated to reinforcing our gastrointestinal portfolio and building the capabilities in our key target geographies: China, France, Russia, Central & Eastern Europe and Algeria. In 2017, we also began to implement the extension of our brands, starting with our flagship Smecta line. We also launched our first probiotic-based food supplement, Smebiocta (for GI disorders) and rolled out our first medical device SmectaGo, a ready-to-use liquid solution against diarrhea.
We have reinforced our portfolio in Europe through the acquisition of five select consumer healthcare products from Sanofi. The most important is Prontalgine®, an analgesic for the treatment of moderate to severe pain. The portfolio also includes Buscopan®, an antispasmodic; Suppositoria Glycerini, a laxative; and the expectorants Mucothiol® and Mucodyne®. This transaction further accelerates the development of our Consumer Healthcare business and our conversion to an OTx (combined prescription and over-the-counter) business model.
We have also acquired an equity stake in Akkadeas Pharma, a privately-held consumer healthcare company in Italy, with an option to take control of the company in the future. Akkadeas Pharma’s diversified portfolio includes probiotics, medical devices and food supplements.
Going forward, our strategic imperatives are to further strengthen our capabilities to serve pharmacists and consumers on top of physicians and patients; to further reinforce our presence in Europe; and to further expand our portfolio through the extension of our existing brands and external acquisitions.
Our areas of expertise
Smecta®, Ipsen’s trusted flagship product, is primarily indicated for the symptomatic treatment of acute diarrhea. A ready-to-use liquid solution is also available in some countries. Other products in this range include Smebiocta® – LP299V®, the first probiotic launched by Ipsen which provides an innovative solution for GI disorders. The GI portfolio also includes Forlax®, an osmotic laxative; Fortrans®, a colon-cleansing solution; and Eziclen®/Izinova®, a second-generation bowel-cleansing preparation.
Tanakan® is a standardi zed, patented ginkgo biloba extract (EGb 761®) for the symptomatic treatment of cognitive disorders such as memory deficit and concentration disturbances in the elderly, and for vertigo and tinnitus.
Adenuric® is a therapy for the management of gout, an inflammatory form of arthritis caused by elevated levels of uric acid in the blood.
Sales in consumer healthcare in 2017
(16,6% of sales in 2017)